HEPATOL RES 润色咨询

HEPATOLOGY RESEARCH

出版年份：1997 年文章数：1255 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：9.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2022-02-17 381302

    请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2021-12-29 msSSSSSD

    引言一般是三段式么？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2021-12-28 小动量

    引言三段式指的是什么?

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2020-06-03 1861eaa8b6m

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2020-10-27 ms9476632540558124

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：肝癌临床回顾性研究，2天秒拒。。。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2019-01-16 ninininininnini

    “EO：XXXXXXX
    under review”是什么意思，是编辑部在处理稿件格式，还是外审中

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2020-03-11 Liuying11

    同问，求各位大神解答155****5276暂无昵称 2020-02-16 发表::
    这个收生信的文章吗    155****5276暂无昵称 2020-02-16 00:00:00 发表:
    这个收生信的文章吗

    155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2020-02-16 1228d76am76暂无昵称

    这个收生信的文章吗

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2019-11-27 貊剑觫

    审稿速度:2.0
    经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10
    January 2019.

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1194468, encodeId=c450119446824, content=请问各位大神，这个杂志的投稿入口在哪里？看不到链接呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea71364949, createdName=381302, createdTime=Thu Feb 17 15:30:25 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091077, encodeId=7bc110910e712, content=引言一般是三段式么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091078, encodeId=d02d10910e892, content=引言三段式指的是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601307, encodeId=730560130ee8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：日本肝病学会办的杂志，审稿很快，5月20投的，稿件号547，6月3号回复，送了2个外审，审稿人很细致，提了几条意见，语气挺友好，两个人意见70%重合，都是一些细节的小问题，最后编辑Not acceptable with Reviewer's Comments，悲剧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fd62045489, createdName=1861eaa8b6m, createdTime=Wed Jun 03 22:43:41 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894715, encodeId=5add894e1535, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：肝癌临床回顾性研究，2天秒拒。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Tue Oct 27 09:39:36 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565664, encodeId=6eee565664bc, content=“EO：XXXXXXX <br> under review”是什么意思，是编辑部在处理稿件格式，还是外审中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/5068c7c7062a4b17bf1e8dfabe4692e9/e45df06dbf754ea18dd1095a9f760023.jpeg, createdBy=32d12441999, createdName=ninininininnini, createdTime=Wed Jan 16 18:38:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586397, encodeId=68cb58639eed, content=同问，求各位大神解答<span class="quote">155****5276暂无昵称 2020-02-16 发表::<br>这个收生信的文章吗</span><span class="quote">155****5276暂无昵称 2020-02-16 00:00:00 发表:<br>这个收生信的文章吗</span>, beContent=155****5276暂无昵称 2020-02-16 发表:: 这个收生信的文章吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/KZBNgla4iaeV8NyshicxHNCqFLdAWkDAG0AxmdMCLxheE6jA9csvJ5fWqQ5ozqDNiclQbVyhOmxJNLyJxegeAloKA/0, createdBy=d2112162916, createdName=Liuying11, createdTime=Wed Mar 11 00:00:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584842, encodeId=58f358484255, content=这个收生信的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98c2340556, createdName=1228d76am76暂无昵称, createdTime=Sun Feb 16 00:00:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580534, encodeId=f41658053409, content=审稿速度:2.0<br>经验分享：Received 11 September 2018; revision 21 December 2018; accepted 10 <br> January 2019., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8db2005109, createdName=貊剑觫, createdTime=Wed Nov 27 15:14:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579960, encodeId=23235e99602c, content=肝脏的毒理可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/16/ac69454112b1d3787e439effcd2313d4.jpg, createdBy=e1201700463, createdName=yinheng0123, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=)]
    2019-11-16 yinheng0123

    肝脏的毒理可以投吗？

    0

共88条页码: 2/9页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分